Compositions and methods for treating cancer with anti-BCMA immunotherapy
US11052112B2 · kind B2 · utility
1Cited by
49References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2020 |
| Grant date | Jul 6, 2021 |
| Priority date | — |
| Expiry date | May 29, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.